Home
Companies
Gilead Sciences

Gilead Sciences

Company

Company Profile

Gilead Sciences is a biopharmaceutical company focused on discovering, developing and delivering innovative therapeutics for people with life-threatening diseases. The company says its work spans more than 35 countries and centers on virology, oncology, and inflammation.

Website: https://www.gilead.com
Headquarters: Foster City, California, USA
Founded: 1987
Stock Ticker: NASDAQ:GILD

Related News

Gilead's Lenacapavir Advances: FDA Accepts Weekly Oral PrEP Application, Global Access Expands

Jun 16, 2026

The U.S. FDA has accepted Gilead's application for an investigational once-weekly oral lenacapavir for HIV prevention, with a review date set for February 2027. Concurrently, PEPFAR and The Global Fund are expanding access to the twice-yearly injectable version to a total of 3 million people by 2028. Gilead will present new data on both lenacapavir and a novel bictegravir/lenacapavir combination at CROI 2026.

Merck/Gilead Discontinue Lung Cancer Trial as Pfizer, Roivant Report Pipeline Updates

Jun 09, 2026

Merck and Gilead discontinued a Phase 3 lung cancer trial due to lack of statistical significance, while Pfizer initiated a new Phase 1 trial and Roivant Sciences completed enrollment in its Phase 2 PHocus trial for pulmonary hypertension.

Gilead Q1 2026 Sales Rise 5% to $6.9B; Full-Year Revenue Guidance Raised by $400M

Jun 08, 2026

Gilead Sciences reported Q1 2026 total product sales of $6.9 billion, up 5% year over year, with HIV revenue growing 10% to $5.0 billion. The company raised its full-year 2026 base business revenue guidance by $400 million to $29.4–$29.8 billion. Non-GAAP diluted EPS was $2.03, up 12%, while the company advanced its oncology and cell therapy pipeline.

FDA Approves AstraZeneca and Daiichi Sankyo's Datroway for First-Line Triple-Negative Breast Cancer

May 22, 2026

FDA approves AstraZeneca and Daiichi Sankyo's Datroway for first-line TNBC patients not eligible for PD-1/L1 inhibitors, based on Phase III TROPION-Breast02 data showing a 21% reduction in risk of death versus chemotherapy.

16 drugmakers announce TrumpRx pricing agreements and direct-to-patient discounts

May 12, 2026

Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.

Pharmaceutical Stocks to Watch Include Eli Lilly, AbbVie, Vertex, Gilead and Pfizer

Apr 23, 2026

Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.

Zimbabwe launches lenacapavir as Kenya becomes fourth African country to start PrEP rollout

Apr 15, 2026

Lenacapavir was launched in Zimbabwe in February 2026 as Kenya became the fourth African country to start administering the twice-yearly HIV prevention injection. The rollout follows launches in Eswatini and Zambia in December 2025, five months after US FDA approval.

Pharmaceutical Market Reports Highlight Key Players Across Multiple Therapeutic Areas

Apr 01, 2026

Market analysis reports project substantial growth through 2033 across sarcopenia treatments, oncology injection drugs, and ASO-based therapies. Major pharmaceutical companies including Pfizer, Merck, Roche, Novartis, and Amgen feature prominently across all three therapeutic areas. The reports cover market segmentation, geographic analysis, and competitive landscapes for each sector.

AI's Mixed Impact on Pharma: Accelerating Drug Development While Facing Clinical Trial Realities

Apr 01, 2026

AI could compress drug development from 10-15 years to as little as six years, accelerating discovery and reducing late-stage trial failures. However, clinical trial execution remains heavily dependent on human oversight, with AI estimated to cut costs only 10-15% while facing regulatory and liability constraints. Major pharma companies like Gilead are investing in AI research centers despite practical limitations in trial implementation.

Gilead Sciences secures $1.5 billion licensing deal for cancer candidate GH31

Mar 20, 2026

Gilead Sciences has agreed a global licensing deal worth up to $1.5 billion with China's Genhouse Bio for its synthetic lethal cancer candidate GH31, a MAT2A inhibitor with IND clearance in the USA and China.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07601243	Study of GS-2426 in Participants With Advanced Solid Tumors	NOT_YET_RECRUITING	PHASE1
NCT07580482	The Referral to Hepatology Can be Improved Through an Electronic Medical Record (EMR)-Based Best Practice Alert (BPA) for an Appropriate Referral	COMPLETED	NA
NCT07560046	Combating Related Epidemics in HCV	NOT_YET_RECRUITING	PHASE4
NCT07546812	Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas	RECRUITING	PHASE2
NCT07530263	Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA)	NOT_YET_RECRUITING	PHASE1
NCT07527858	Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer	NOT_YET_RECRUITING	PHASE2
NCT07476339	REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE	NOT_YET_RECRUITING	PHASE4
NCT07474558	SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates	NOT_YET_RECRUITING	PHASE2
NCT07473778	Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention	RECRUITING
NCT07462611	HIV Pre-Exposure Prophylaxis (PrEP) Linkage With Immediate Medications in the Emergency Department Study	NOT_YET_RECRUITING	NA